Serelaxin, recombinant human relaxin-2, for heart failure patients
A systematic review and meta-analysis

Ling Yu, PhD\textsuperscript{a}, Lijuan Cao, PhD\textsuperscript{a}, Jing Sun, MD\textsuperscript{b}, Zhongyi Li, MMed\textsuperscript{c}, Fengzhen Yao, MD\textsuperscript{a},*, Yabin Zhou, MD\textsuperscript{b},*

Abstract
Background: Serelaxin, recombinant human relaxin-2, is a hormone with vasodilatory and end-organ protective effects. Recently, it has been licensed to treat acute decompensated heart failure. Here, a systematic review and meta-analysis on randomized controlled trials (RCTs) was performed to assess the effect of serelaxin on mortality and dyspnea improvement in patients with heart failure.

Methods: RCTs comparing serelaxin treatment to other heart failure treatments were searched in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. The main endpoints were mortality and dyspnea improvement. Pooled data were assessed by using a random effects model.

Results: A total of 451 studies were identified, of which 8 studies (8477 participants) were eligible and included in our analysis. Compared with other heart failure treatment group, serelaxin group had no effect on 30-day, 60-day, and 180-day mortality (OR, 0.79; 95% CI, 0.65–0.96). Compared with control group, there was no effect on dyspnea improvement.

Conclusion: Serelaxin treatment is irrelevant with the mortality, and it cannot improve dyspnea of heart failure patients.

Abbreviations: AHF = acute heart failure, NYHA = New York Heart Association, OR = odds ratio, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses, RCTs = randomized controlled trials.

Keywords: heart failure, mortality, recombinant human relaxin-2, Serelaxin

1. Introduction
Acute heart failure (AHF) is a common and occasionally life-threatening disease. As the aging society, the burden of heart failure on health services is expected to rise, with increased healthcare expenditure and activity.\cite{1} Additionally, the economic burden associated with the treatment of AHF has been further increased by an elevated rate of readmissions, which reaches 25% at 30 days and 30% at 60 to 90 days after discharge.\cite{2} The major medical and economic burdens of this disease have created a large demand for systems-wide changes in health care delivery as well as new therapies with positive impacts on AHF mortality and readmissions.\cite{3}

Serelaxin is a recombinant form of the pregnancy hormone relaxin-2, the hormone regulates maternal adaptations to improve arterial compliance, cardiac output, and renal blood flow.\cite{4} Serelaxin has a unique mechanism of acting that could potentially address the complex pathophysiology of AHF through multiple pathways, possibly leading to organ protection.\cite{5-7}

However, The RELAX-AHF-2 trial showed that short-term intravenous infusion of serelaxin did not reduce mortality compared with placebo in patients with AHF. Paradoxically, pre-RELAX-AHF trial suggested that the treatment of AHF with serelaxin could significantly reduce mortality compared with the control group.\cite{8} RELAX-AHF trial also showed similar outcomes after serelaxin treatment.\cite{9} A series of clinical trials have assessed indicators of dyspnea, which showed different results.

In order to clarify the conflicting opinions, we therefore performed a systematic review and meta-analysis on randomized controlled trials to investigate the role of serelaxin in mortality and dyspnea improvement in patients with AHF.

2. Methods

2.1. Literature research
Our meta-analysis was registered at International Prospective Register of Systematic Reviews (No.: CRD42017058860) and followed the PRISMA statement (Reporting Items for Systematic Reviews and Meta-Analyses).
A literature search of Web of Knowledge, Embase, ClinicalTrials.gov, and PubMed from Jan 1, 1950 to December 1, 2017 was conducted without language restrictions. A combination of the following keywords was used: “Serelaxin” and “Heart Failure.” The complete search used for PubMed was as follows: (serelaxin protein, human [MeSH] OR serelaxin protein, human OR human relaxin-2 OR RLN2 protein, human OR relaxin H2, human OR relaxin-2 protein, human or H2 relaxin, human OR Recombinant Proteins, human OR Recombinant Fusion Proteins, human) AND (Heart Failure [MeSH] OR Heart Failure OR Cardiac Failure OR Heart Decompensation OR Decompensation, Heart OR Heart Failure, Right-Sided OR Heart Failure, Right Sided OR Right-Sided Heart Failure OR Right-Sided Heart Failure OR Right-Sided Heart Failure OR Right-Sided Heart Failure OR Left-Sided OR Heart Failure, Left Sided OR Left-Sided Heart Failure OR Left-Sided Heart Failure OR Myocardial Failure OR Congestive Heart Failure OR Heart Failure, Congestive). Additional studies were also obtained by manually screening the references list.

2.2. Eligibility criteria and data extraction

Studies were considered eligible if they met the following inclusion criteria: randomized clinical trials in adults with heart failure; compared serelaxin to another treatment strategies; reported changes in mortality or the dyspnea improvement during the trial. Studies were excluded if they were: only published in the abstract; not randomized controlled trial (RCT); the absence of intention to treatment data; or no treatment for patients with heart failure.

We compared serelaxin to any other treatment strategies regardless of previous treatment. The outcomes assessed were as follows: mortality at any time during the experiment, changes in dyspnea between baseline and the end of intervention.

Table 1: Characteristics of the included studies.

| Author                  | Year     | Different interventions | Design          | Duration of interventions, hours | Follow-up | Randomized patients (Serelaxin/Control) | Number of men | Mean age |
|-------------------------|----------|-------------------------|-----------------|----------------------------------|-----------|----------------------------------------|---------------|----------|
| John R Teerlink         | 2009     | Serelaxin vs placebo    | DB-P            | 48                               | 180 days  | 229 (168/61)                          | 128 (55.9%)   | 70.3     |
| John R Teerlink         | 2013     | Serelaxin vs placebo    | DB-P            | 48                               | 180 days  | 1161 (581/580)                        | 725 (62.4%)   | 72       |
| Piotr Piorunowski       | 2013     | Serelaxin vs placebo    | DB-P            | 20                               | 30 days   | 71 (34/37)                            | 53 (74.6%)    | 68.6     |
| Marion Dahlke           | 2014     | Serelaxin vs placebo    | DB-P            | 48                               | 10 days   | 40 (32/8)                             | 15 (37.5%)    | 29.8     |
| Adriaan A. Voors        | 2014     | Serelaxin vs placebo    | DB-P            | 24                               | 28 hours  | 65 (28/37)                            | 58 (69.2%)    | 67.9     |
| Naoki Sato              | 2015     | Serelaxin vs placebo    | DB-P            | 48                               | 60 days   | 46 (31/15)                            | 34 (73.9%)    | 75.3     |
| John R Teerlink         | 2016     | Serelaxin vs placebo    | DB-P            | 48                               | 16 weeks  | 320 (212/108)                        | Not available  | Not available |
| John R Teerlink         | 2017     | Serelaxin vs placebo    | DB-P            | 48                               | 180 days  | 6545 (3274/3271)                      | 3927 (60%)    | 73.0     |

NYHA classification, n (%)

| Author                  | Year     | Class I | Class II | Class III | Class IV | Mean baseline dyspnea (%) | Mortality event (Nesiritide/Control) |
|-------------------------|----------|---------|----------|-----------|----------|----------------------------|--------------------------------------|
| John R Teerlink         | 2009     | 3 (12%) | 1 (3.9%) | 49 (119%) | 9 (20.5%)| 100                        | 12/8                                 |
| John R Teerlink         | 2013     | 12 (31%)| 16 (41.1%)| 20 (53.1%)| 8 (20.5%)| 102                        | 42/65                                |
| Piotr Piorunowski       | 2013     | N/A     | N/A      | N/A       | N/A      | Not available              | 2/2                                  |
| Marion Dahlke           | 2014     | N/A     | N/A      | N/A       | N/A      | Not available              | 0/0                                  |
| Adriaan A. Voors        | 2015     | 17 (67.7%)| 11 (39.3%)| N/A       | N/A      | Not available              | 0/0                                  |
| Naoki Sato              | 2015     | 1 (3.3%)| 6 (19.4%)| 3 (9.7%)  | 2 (6.5%) | 100                        | 0/0                                  |
| John R Teerlink         | 2016     | N/A     | N/A      | N/A       | N/A      | Not available              | 285/291                             |
| John R Teerlink         | 2017     | N/A     | N/A      | 3011 (46%)| 720 (11%)| Not available              | Not available                        |
was completed. Around 7 studies were conducted in multiple centers, and only 1 study was carried out at a single center. Whether participants and outcome assessors were marked to treatment allocation was specified in all studies. Risks of bias are shown in Figures 1 and 2. About 30-day mortality was evaluated in 4 trials (n=1337) shown in Figure 3, 60-day mortality was reported in 3 trials (n=7935) shown in Figure 5. Dyspnea was reported in 3 trials (n=1436) shown in Figure 6. Dosage of serelaxin ranged from 10 to 250 μg/kg per day, and the duration of interventions lasted from 20 to 48 hours. Compared with control group, results of the 30-day (OR, 0.66; 95% CI, 0.33–1.32), 60-day (OR, 0.64; 95% CI, 0.37–1.10) and 180-day mortality (OR, 0.75; 95% CI, 0.52–1.09) suggested that there was no significant difference. Compared with control group, there was no significant difference in dyspnea in serelaxin group (OR, 1.41; 95% CI, 1.00–1.98). The heterogeneity of 8 studies was assessed, with \( I^2 \) of 0% to 59%. No publication bias was found in all the analyses.

Serelaxin treatment is not related to either the long-term or short-term mortality, and cannot improve dyspnea in patients with heart failure. Meanwhile, serelaxin is well tolerated and safe in patients with AHF, and no serious drug-related adverse events have been reported yet. Nevertheless, further testing and approval is required for serelaxin.

4. Discussion

Compared with other heart failure treatments, serelaxin did not significantly decrease mortality, with no remarkable improvement in dyspnea. These data suggested that serelaxin, as a therapeutic strategy, did not improve the mortality of heart failure patients. AHF is a common reason for hospitalization or death, and it places a heavy economic burden on society.\(^{15}\) The prevalence of AHF is difficult to assess, according to a recent statistic, there are about 1% to 12% AHF globally.\(^{16}\) At present, no AHF therapy receives Level I and Class A recommendation from guidelines\(^{17,18}\) highlighting the lack of robust evidence from randomized studies. Unfortunately, the treatments of AHF have not made much progress in the last 4 decades.\(^{19}\) Serelaxin has been proved to have beneficial clinical and hemodynamic effects without serious adverse effects in many randomized controlled trials.

Several RCTs on serelaxin treatment for AHF have been performed since 2017, after analyzed the short-term and long-
term follow-up results, we firstly revealed that there was no reduction in mortality of heart failure patients treated by serelaxin. Short-term, long-term mortality, and hospital readmission rates are major indicators to assess the therapeutic effects. Unfortunately, our results indicated that serelaxin would not be considered as first-line therapy of AHF, for it failed to reduce the mortality of AHF. In conclusion, all the currently available RCTs of serelaxin treatment of AHF were included in our study, and our results revealed that serelaxin failed to reduce the mortality of patients with AHF.

There are also some limitations in this analysis. Firstly, the long-term durability of this treatment was unknown. Secondly, although most research was published in high-impact journals, there was still potential risk of bias, such as open-label design. Thirdly, safety, long-term durability, and side effects of serelaxin are still unclearly. Finally, there are still too less treatment efficacy
indicators, and more clinical indicators remain to be explored in the future.

**Author contributions**

Contributor ship statement: FZY, YBZ, LY, and LJC designed the study. LJC, JS, LY, and JS collected and analyzed the data. LJC wrote the manuscript with input from all authors, and YBZ and JS discussed the results and agreed the final vision. LY, LJC, JS, and YBZ supervised the project.

**Conceptualization:** Ling Yu, Lijuan Cao, Fengzhen Yao, Yabin Zhou.

**Data curation:** Lijuan Cao.

**Formal analysis:** Lijuan Cao.

**Funding acquisition:** Zhongyi Li.

**Methodology:** Zhongyi Li.

**Resources:** Ling Yu.

**Software:** Zhongyi Li, Yabin Zhou.

**Supervision:** Jing Sun, Yabin Zhou.

**Validation:** Jing Sun, Fengzhen Yao.

**Visualization:** Jing Sun, Fengzhen Yao.

**Writing—original draft:** Ling Yu, Jing Sun.

**Writing—review & editing:** Yabin Zhou.

**References**

[1] Vazir A, Cowie MR. Decongestion: diuretics and other therapies for hospitalized heart failure. Indian Heart J 2016;68(suppl 1):s61–8.

[2] Varr BC, Maurer MS. Emerging role of serelaxin in the therapeutic armamentarium for heart failure. Curr Atheroscler Rep 2014;16:447.

[3] Ghoshthale M, Vaduganathan M, Fonarow GC, et al. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013;61:391–403.

[4] Teerlink JR, Voors AA, Ponikowski P, et al. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur J Heart Fail 2017;19:800–9.

[5] Teichman SL, Unemori E, Teerlink JR, et al. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7:75–82.

[6] Du XJ, Rathgate RA, Samuel CS, et al. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 2010;7:48–58.

[7] Conrad KP, Shroff SG. Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 2011;13:409–20.

[8] Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase Ib study. Lancet 2009;373:1429–39.

[9] Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29–39.

[10] Ponikowski P, Mitrovic V, Ruda M, et al. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 2014;35:431–41.

[11] Dahlke M, Ng D, Yamaguchi M, et al. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian population. J Clin Pharmacol 2015;55:415–22.

[12] Voors AA, Dahlke M, Meyer S, et al. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study. Circ Heart Fail 2014;7:994–1002.

[13] Sato N, Takahashi W, Hirayama A, et al. Multicenter, randomized, double-blinded, placebo-controlled phase I study of serelaxin in Japanese patients with acute heart failure. Circ J 2015;79:1237–47.

[14] Teerlink JR, Saini R, Guillestad L, et al. RELAX-REPEAT: a multicenter, prospective, randomized, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure. J Cardiac Fail 2016;22:214–5.

[15] Passantino A, Montillo F, Iacoviello M, et al. Predicting mortality in patients with acute heart failure: Role of risk scores. World J Cardiol 2015;7:902–11.

[16] Searle J, Frick J, Möckel M. Acute heart failure facts and numbers: acute heart failure populations. ESC Heart Fail 2016;3:65–70.

[17] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:981–975.

[18] O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362–425.

[19] Hunter Jr, Martindale J, Abdul-Hafez O, et al. Approach to acute heart failure in the emergency department. Progress in cardiovascular diseases. Prog Cardiovasc Dis 2017;60:178–86.

[20] Najafi F, Jamrozik K, Dobson AJ. Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure. Eur J Heart Fail 2009;11:472–9.